Coagulation

Global In-Vitro Diagnostics (IVD) Market Trends Report 2022 - Opportunities Emerging in Artificial Intelligence Future Trends, At-Home Testing, Microfluidics in IVD, & Telehealth - ResearchAndMarkets.com

Retrieved on: 
Friday, March 17, 2023
Health, Other Health, Clinical chemistry, Immunochemistry, Hematology, Mass spectrometry, NGS, COVID-19, Segment, Movement, Infection, ...Continued, OTC, HPV, IVD, Antigen, POC, Major Trends in Jewish Mysticism, Video game, Pharmaceutical industry, Vaccine, Microbiology, Coagulation, Immunoassay, Serology, Growth

This report is an update of the market for in vitro diagnostics products from the analysts to reflect the latest information as of Q3 2022 with a publication date of November 2022.

Key Points: 
  • This report is an update of the market for in vitro diagnostics products from the analysts to reflect the latest information as of Q3 2022 with a publication date of November 2022.
  • What's Driving Growth in the IVD Market in Q3 and the last half of 2022?
  • What Major Trends are Affecting the Market in Q3 and the last half of 2022?
  • What Product Trends and New Developments Will Shape the IVD Market in the last half of 2022?

Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC

Retrieved on: 
Monday, March 6, 2023
Membrane, Protein, MBA, Environmental impact of fracking in the United States, EPA, Mineral oil, Thrombosis, Bleeding, Professional corporation, Atherosclerosis, Research, Acute coronary syndrome, Corn oil, Patient, Risk, Antioxidant effect of polyphenols and natural phenols, ACS, DHA, Congress, Harvard Medical School, Coagulation, Doctor of Philosophy, LDL, Eicosapentaenoic acid, Dietary supplement, Pharmaceutical industry, Medicine

DUBLIN, Ireland and BRIDGEWATER, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted new in vitro data supporting the potential mechanistic effects of eicosapentaenoic acid (EPA) in reducing cardiovascular events in at-risk patients presented at the joint ACC.23 together with the World Congress of Cardiology (ACC.23/WCC) in New Orleans, LA, March 4-6, 2023.

Key Points: 
  • “The findings shared at ACC.23/WCC provide additional insight into the unique role of EPA in reducing cardiovascular events in at-risk patients around the world.
  • These mechanisms may help explain the significant risk reduction benefit demonstrated in the REDUCE-IT trial for icosapent ethyl.
  • By contrast, EPA significantly inhibited sdLDL and VLDL oxidation by 75% and 94%, respectively, compared with vehicle (p
  • While DHA exhibited antioxidant activity at 2 hours at a level less than EPA, this effect was eliminated by 4 hours.

VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer

Retrieved on: 
Wednesday, March 8, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Woman, CSO, Clinical trial, Regenerative medicine, American Heart Association, Bleeding, Dialysis, Bangladesh Technical Education Board, American Board of Commissioners for Foreign Missions, Moyamoya disease, Leiden University Medical Center, Pathology, VASA, Department of Defense Serum Repository, Coagulation, Hemostasis, Special, Duke University Hospital, Knowledge, Tissue engineering, Coagulopathy, NIH, Pharmaceutical industry, Medical device, KHI

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Jeffrey Lawson as its new Chief Scientific Officer (CSO).

Key Points: 
  • VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Jeffrey Lawson as its new Chief Scientific Officer (CSO).
  • Dr. Lawson will take over the role from Prof. Dr. Pieter Reitsma, CSO and founder of VarmX, who will continue to serve as a special advisor to the Company.
  • Dr. Lawson and Prof. Dr. Reitsma will work closely to ensure a smooth transition and the continued scientific development of the company’s innovative technologies.
  • Dr. Jan Öhrström, CEO of VarmX, said: “We are delighted to welcome Jeff to the team at VarmX.

Coagulant Therapeutics Announces Publication in Blood Advances Describing Novel Nanobody Library to Activated Protein C (APC) and Initial Leads for Treatment of Trauma and Hemophilia

Retrieved on: 
Monday, February 27, 2023
Hook effect, Therapy, Internal bleeding, Molecular medicine, Mortality, Coagulation, Disease, Scripps Research, Journal, Sepsis, American Society of Hematology, Haemophilia, Coagulant, Inflammation, APC, Research fellow, Manuscript, Antibody, Activated protein C resistance test, Cell, Health, Society, Trauma, Pharmaceutical industry

BERKELEY, Calif., Feb. 27, 2023 /PRNewswire/ -- Coagulant Therapeutics Corporation, a privately held company focused on the design, development and commercialization of therapeutics targeted to the coagulation cascade and its adjacencies, announced the online publication of a manuscript titled "Selective Modulation of Activated Protein C Activities by a Non-Active Site Targeting Nanobody Library" in the journal Blood Advances, a Journal of the American Society of Hematology.

Key Points: 
  • Developing APC-based therapeutics that selectively eliminate or retain these functions individually, or in combination, has been challenging.
  • Leveraging the unique properties of llama antibodies (referred to as nanobodies) the manuscript describes the generation of a novel nanobody library to APC.
  • This represents a tool chest for APC targeted therapies that has already identified a lead candidate for the treatment of trauma and hemophilia.
  • "The ability of the Coagulant Therapeutics APC nanobody library to selectively change the activity profile of APC is quite amazing."

Global In-Vitro Diagnostics (IVD) Market Report 2022: Sector to Reach $144.7 Billion by 2027 at a 4.6% CAGR

Retrieved on: 
Sunday, January 22, 2023
USD, Cardiology, Diagnosis, Diabetes, Microbiology, Data management, IVD, Immunoassay, Growth, Government, Region, Hemostasis, Infection, Prevalence, POC, Hospital, HIV/AIDS, Patient, Coagulation, Hospital Clinic Manuel Quintela, Nephrology, Medical device, Urinalysis, Software, Hematology

The global in-vitro market is projected to reach USD 144.7 billion by 2027 from USD 115.8 billion in 2022, at a CAGR of 4.6%.

Key Points: 
  • The global in-vitro market is projected to reach USD 144.7 billion by 2027 from USD 115.8 billion in 2022, at a CAGR of 4.6%.
  • On the basis of product and service, the IVD market is segmented into reagents & kits, instruments, services, and data management software.
  • Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies.
  • The IVD market in the Asia-Pacific region is projected to register the highest CAGR during the forecast period.

Taking on the Greatest Threat to Healthspan, A4M Unveils 31st Spring Congress Program Featuring Top Experts La Puma, Rifai, and Lufkin

Retrieved on: 
Tuesday, February 7, 2023
Health, Inflammation, American Academy, Cardiovascular disease, Longevity, Congress, Cancer, Fire, Insomnia, Coagulation, Harvard University, Anti-aging movement, Gaylord Palms Resort & Convention Center, Conditional sentence, Learning, Obesity, A4M, Occupational burnout, Alzheimer's disease, Ageing, Growth, Hypertension, Degenerative disease, Doctor of Philosophy, Pharmaceutical industry, MD

This year, A4M tackles one of the greatest threats to longevity and healthspan: inflammation.

Key Points: 
  • This year, A4M tackles one of the greatest threats to longevity and healthspan: inflammation.
  • With the expert insight of modern medicine's most influential voices, the program delves into the latest therapeutic approaches to this common disease pathway.
  • A star-studded panel of educators headlines this year's event, including internationally recognized keynote speakers Tom Rifai, MD, and John La Puma, MD.
  • The Spring Congress agenda closely examines interconnected biological systems and the underlying pathways contributing to inflammatory conditions, from autoimmune diseases to hormone health.

Global In-Vitro Diagnostics (IVD) Market Report 2022: Introduction of Disease-Specific Biomarkers and Tests Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 18, 2023
Biotechnology, Health, Medical Devices, Hospital, Degenerative disease, Immunoassay, Infection, Hemostasis, HIV/AIDS, Clifton Springs Hospital & Clinic, POC, Microbiology, Nephrology, Government, IVD, Coagulation, Cardiology, Urine test strip, Diagnosis, Growth, Diabetes, Region, Prevalence, Patient, Data management, USD, Medical device, Clinical urine tests, Software, Hematology

The global in-vitro market is projected to reach USD 144.7 billion by 2027 from USD 115.8 billion in 2022, at a CAGR of 4.6%.

Key Points: 
  • The global in-vitro market is projected to reach USD 144.7 billion by 2027 from USD 115.8 billion in 2022, at a CAGR of 4.6%.
  • On the basis of product and service, the IVD market is segmented into reagents & kits, instruments, services, and data management software.
  • The reagents & kits segment accounted for the largest share of the IVD market in 2021.
  • Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies.

Europe Medical Diagnostics Market Report 2022: Expansion of Medical Devices Industry Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023
Health, General Health, Immunoassay, Attention, COVID-19, POC, Synlab Group, Hematology, Pandemic, Government, Precision medicine, IVD, Coagulation, Infection, Diagnosis, Growth, Quest Diagnostics, Eurofins Scientific, Clinical chemistry, Urbanization, Sonic Healthcare, LabCorp, US, Pharmaceutical industry, Medical device

The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2023-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2023-2027)" report has been added to ResearchAndMarkets.com's offering.
  • European medical diagnostics market is expected to reach US$104.01 billion in 2027, growing at a CAGR of 4.52%, for the time period of 2023-2027.
  • Factors such as rise in number of new cancer cases, expansion of medical device industry, growth in geriatric population, accelerating demand for In-Vitro Diagnostic (IVD) and rapid urbanization would drive the growth of the market.
  • As a result of this, the demand for immunoassays is rising, which is aiding the market growth of medical diagnostics in Europe.

Werfen Receives 2022 IMV ServiceTrak Awards for Best Customer Satisfaction and Best Service in Hemostasis and Blood Gas

Retrieved on: 
Wednesday, January 4, 2023
Hemostasis, Original equipment manufacturer, GEM, CO-oximeter, ACL, NOVA, Chrysler, Strategic planning, Autoloader, Name, ACD, Blood, Catheter, Patent, Automation, Thrombosis, Agilent ChemStation, IBM Aptiva, Originality, Data management, Hospital, High-dependency unit, Health care, Accreditation, Coagulopathy, Information technology, OEM, Commercial Operating System (COS), POC, IMV, Pharmaceutical industry, Medical device, Medical imaging, Science, Autoimmunity, Werfen, Coagulation

BEDFORD, Mass., Jan. 4, 2023 /PRNewswire/ -- Werfen today announced that it has received five 2022 IMV ServiceTrak Awards including Best System Performance and Best Service in the Coagulation (Hemostasis) category, as well as Best Customer Satisfaction, Best System Performance and Best Service in the Blood Gas category.

Key Points: 
  • BEDFORD, Mass., Jan. 4, 2023 /PRNewswire/ -- Werfen today announced that it has received five 2022 IMV ServiceTrak Awards including Best System Performance and Best Service in the Coagulation (Hemostasis) category, as well as Best Customer Satisfaction, Best System Performance and Best Service in the Blood Gas category.
  • IMV ServiceTrak 2022 Clinical Laboratory Awards are presented to manufacturers whose customers are highly satisfied with their products and services.
  • Results are based on interviews conducted with respondents in 1,716 clinical testing locations in the US, representing 2,169 instruments.
  • "It's an incredible honor to have the quality of our products and customer service, in both our Hemostasis and Acute Care Diagnostics business lines, recognized among the winners of the 2022 IMV awards," said Bill Crandell, Vice President of Commercial Operations, North America at Werfen.

2023 Healthcare Trend: Growth in $21 Billion Molecular Diagnostics Market

Retrieved on: 
Tuesday, January 3, 2023
Knowledge, Infection, Roche Diagnostics, RT, COVID, Knowledge-centered support, Gen-Probe, BD (company), Growth, COVID-19, Tuberculosis, Publishing, Neisseria gonorrhoeae, HIV, Coagulation, IVD, Cancer, Chlamydia trachomatis, Pharmaceutical industry, Science

ARLINGTON, Va., Jan. 3, 2023 /PRNewswire-PRWeb/ -- There is a market in excess of $21 billion for molecular testing technologies, reveals medical market research publisher Kalorama Information in The World Market for Molecular Diagnostics Tests, 11th Edition, a recent report added to the firm's Knowledge Center subscription. The majority of the market is COVID-19, but there remains a $10 billion dollar market for all other molecular in vitro diagnostics (IVD).

Key Points: 
  • ARLINGTON, Va., Jan. 3, 2023 /PRNewswire-PRWeb/ -- There is a market in excess of $21 billion for molecular testing technologies, reveals medical market research publisher Kalorama Information in The World Market for Molecular Diagnostics Tests, 11th Edition , a recent report added to the firm's Knowledge Center subscription .
  • The majority of the market is COVID-19, but there remains a $10 billion dollar market for all other molecular in vitro diagnostics (IVD).
  • Kalorama Information estimates a $11 billion dollar market for 2022 for COVID-19 molecular diagnostics testing.
  • "Recent growth in molecular diagnostics methods has also been coming from inherited diseases, cancer, coagulation, and other areas."